Walter Dan Weaver, MD | |
619 Sw Corporate View, Topeka, KS 66615-1233 | |
(785) 235-3322 | |
(785) 246-6258 |
Full Name | Walter Dan Weaver |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Location | 619 Sw Corporate View, Topeka, Kansas |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225148877 | NPI | - | NPPES |
049567 | Other | KS | BCBS OF KS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 04-14491 (Kansas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Walter Dan Weaver, MD 619 Sw Corporate View, Topeka, KS 66615-1233 Ph: (785) 235-3322 | Walter Dan Weaver, MD 619 Sw Corporate View, Topeka, KS 66615-1233 Ph: (785) 235-3322 |
News Archive
PumpStart, a community service-learning program created by students at Boston University School of Medicine, that teaches hands-only CPR to the general public, is effective for both teaching high school students a life-saving skill and providing medical students with an opportunity to engage in public health and medical education.
There may be a link between exposure to light during pregnancy and fetal brain development. New findings by researchers at UmeƄ University, Sweden, working in collaboration with American colleagues, may provide better understanding of certain neurological diseases later in life.
Glowpoint, Inc., a provider of cloud-based managed services for telepresence, video conferencing and collaboration, today announced that Guardian 24/7, a health care provider for high-profile executives, has selected Glowpoint's video managed services for providing remote diagnosis and patient collaboration using high-quality video conferencing.
Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.
› Verified 3 days ago
Trent L. Vande Garde, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 619 Sw Corporate View, Topeka, KS 66615 Phone: 785-235-3322 Fax: 785-235-1217 | |
Rita R. Tablante, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 619 Sw Corporate View, Topeka, KS 66615 Phone: 785-235-3322 Fax: 785-246-6258 | |
Thomas J Ashley, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1616 Sw 8th Ave, Topeka, KS 66606 Phone: 785-233-2280 Fax: 785-233-6918 | |
Randall J Kresie, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 6001 Sw 6th Ave, Suite 210, Topeka, KS 66615 Phone: 785-233-0011 Fax: 785-233-1292 | |
Dr. Babak Marefat, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 823 Sw Mulvane St, Topeka, KS 66606 Phone: 785-354-9591 | |
Dr. Gray W Woods, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1500 Sw 10th Ave, Topeka, KS 66604 Phone: 785-354-5613 Fax: 785-354-6426 |